Table 1.
Clinical trials of oncolytic viruses of different types
| Application in cancers | Trial registration ID | NCT02759588 | NCT03206073 | NCT04282044 | NCT04226066 | NCT03256344 | NCT04452591 | NCT03896568 | NCT02923466 | NCT04043104 | NCT00348842 | NCT02068794 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intervention: trial phase | GL-ONC1: Phase 1b & 2 |
Pexa-Vec: Phase I/II |
vvDD:Phase 1 | T601: Phase I/IIa | T-VEC:Phase 1b | CG0070:Phase 3 | DNX-2401:Phase I | VSV-IFNβ-NIS: Phase 1 | AAV2hAQP1: Phase 1/2 |
Pre-clinical | Phase I/II | |
| Construction strategy | Triple deletion of TK/VGF/F14.5 | Deletion of TK and insertion of hGM-CSF | Dual deletion of TK and VGF | Dual deletion of TK/RR and insertion of FCU1 | Dual deletion of ICP34.5/ICP47 and insertion of GM-CSF | Utilization of E2F-1 promoter to directselective expression of E1A and GM-CSFin RB-defective cells | Utilization of a RB binding-defective E1A and insertion of a peptide targeting cancer cell-expressing integrins | Insertion of interferon-beta (IFN-β) and the sodium iodide symporter (NIS) for possible combination with radiotherapy | Insertion of hAQP1 for correcting radiotherapy-associated salivary hypofunction |
Undisclosed | Insertion of NIS for possible combination withradiotherapy |
|
| Targeted cancer | Ovarian Cancer | Refractory Colorectal Cancer | Advanced Solid Tumors | Advanced Malignant Solid Tumors | Breast Cancer and Colorectal Cancer | Non-Muscular Invasive Bladder Cancer | Recurrent High-Grade Glioma | Refractory Solid Tumors | Head and Neck Cancer | Oesophago-gastric Cancer | Recurrent Ovarian Cancer | |
| Oncolytic virus type | Vaccinia virus (VV) | Herpes Simplex Virus(HSV) | Adenovirus(A 4dV) | Vesicular Stomatitis Virus(VSV) | Adenovirus Associated Virus(AAV) | Newcastle disease virus(NDV) | Measles Virus(MV) | |||||